Alvotech (ALVO) Competitors $9.19 +0.26 (+2.91%) As of 07/3/2025 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, and ELANShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Alvotech (NASDAQ:ALVO) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Which has better valuation & earnings, ALVO or ASND? Alvotech has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$585.60M4.73-$231.86M$0.3724.84Ascendis Pharma A/S$393.54M27.04-$409.12M-$6.28-27.72 Do analysts prefer ALVO or ASND? Alvotech currently has a consensus target price of $18.00, indicating a potential upside of 95.87%. Ascendis Pharma A/S has a consensus target price of $220.67, indicating a potential upside of 26.77%. Given Alvotech's higher possible upside, equities analysts clearly believe Alvotech is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ALVO or ASND? In the previous week, Alvotech had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 7 mentions for Alvotech and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.99 beat Alvotech's score of 0.74 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ALVO or ASND more profitable? Alvotech has a net margin of 16.42% compared to Ascendis Pharma A/S's net margin of -93.22%. Ascendis Pharma A/S's return on equity of 0.00% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech16.42% -36.37% 12.70% Ascendis Pharma A/S -93.22%N/A -33.29% Which has more volatility & risk, ALVO or ASND? Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. SummaryAlvotech beats Ascendis Pharma A/S on 8 of the 13 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69B$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E Ratio24.8421.5627.4020.24Price / Sales4.73277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book-6.717.518.085.67Net Income-$231.86M-$55.05M$3.16B$248.47M7 Day Performance0.55%4.59%2.81%3.29%1 Month Performance-15.14%4.86%3.69%5.18%1 Year Performance-24.36%5.82%35.30%21.35% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech3.519 of 5 stars$9.19+2.9%$18.00+95.9%-24.4%$2.69B$585.60M24.841,032ASNDAscendis Pharma A/S3.5573 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017Analyst ForecastVTRSViatris3.2791 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.33B-2.7932,000QGENQiagen4.0702 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3889 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.7454 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6594 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$8.03B$42.28M-48.5330Analyst ForecastBBIOBridgeBio Pharma4.7106 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$7.92B$221.90M-11.95400Insider TradeAnalyst RevisionROIVRoivant Sciences1.9654 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.5734 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.2612 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.68B$4.44B18.059,000Analyst Forecast Related Companies and Tools Related Companies ASND Competitors VTRS Competitors QGEN Competitors MRNA Competitors BPMC Competitors VRNA Competitors BBIO Competitors ROIV Competitors RVMD Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
